Overall, these results suggest that inhibiting HSP90β may be a potential therapeutic treatment of lipid disorders and corylin may become a promising lead compound to treat obesity-induced fatty liver disease, type 2 diabetes and atherosclerosis. The gene discussed is HSP90AB1; the disease is obesity disorder.